Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism

Nature Genetics volume 10, pages 486–488 (1995)Cite this article

An Erratum to this article was published on 01 September 1995

Abstract

Genetic studies on Alzheimer's disease (AD), a devastating neurodegenerative disorder, have identified the apolipoprotein E (APOE) gene as a strong susceptibility marker for AD1–2. TheE*4 allele of APOE is a major risk factor for AD regardless of age of onset or family history3. However, the observation that the APOE*4 allele is neither necessary nor sufficient for the expression of AD emphasizes the involvement of other environmental or genetic elements that, either in conjunction with APOE*4 or alone, increase an individual's risk of developing AD. Among the candidate genes that may affect the risk of this multifactorial disease is the gene coding for α1 -antichymotrypsin (ACT). Like APOE protein, ACT binds to β-amyloid peptide (ApP) with high affinity in the filamentous deposits found in the AD brain4–10 and serves as a strong stimulatory factor in the polymerization of AβP into amyloid filaments10. In AD brains, ACT expression is enhanced, particularly in areas that develop amyloid plaques4–8, 11–12, suggesting that ACT may play an important role in the pathogenesis of AD. Here we show that a common polymorphism in the signal peptide of ACT13 confers a significant risk for AD. Furthermore, the APOE*4 gene dosage effect associated with AD risk is significantly modified by the ACT polymorphism. We have also identified a unique combination of the ACT/AA and APOE 4/4 genotypes as a potential susceptibility marker for AD, as its frequency was 1/17 in the AD group compared to 1/313 in the general population control. Our data show that ACT behaves as a modifier gene that alters the AD risk conventionally associated with the APOE*4 allele.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Strittmatter, W.J. et al. Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheirner disease. Proc. natn. Acad. Sci. U.S.A. 90, 1977–1981 (1993).

    Article  CAS  Google Scholar 

  2. Saunders, A.M. et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467–1472 (1993).

    Article  CAS  Google Scholar 

  3. Kamboh, M.I. Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. Hum. Biol. 67, 195–215 (1995).

    CAS  PubMed  Google Scholar 

  4. Abraham, C.R., Selkoe, D.J. & Potter, H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52, 487–501 (1988).

    Article  CAS  Google Scholar 

  5. Abraham, C.R., Shirahama, T. & Potter, H. α1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein: amyloid and cell localization of α1-antichymotrypsin. Neurobiol. Aging 11, 123–129 (1990).

    Article  CAS  Google Scholar 

  6. Picken, M.M. et al. Distribution of the protease inhibitor α1 -antichymotrypsin in cerebral and systemic amyloid. J. Neuropathol. exp. Neurol. 49, 41–48 (1990).

    Article  CAS  Google Scholar 

  7. Rozemuller, J.M. et al. Distribution pattern and functional state of α1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease. Acta Neuropath. 82, 200–207 (1991).

    Article  CAS  Google Scholar 

  8. Shoji, M. et al. Alpha 1-antichymotrypsin is present in diffuse senile plaques: a comparative study of β-protein and α1-antichymotrypsin immunostaining in the Alzheimer brain. Am. J. Path. 138, 247–257. (1991).

    CAS  PubMed  Google Scholar 

  9. Fraser, P.E., Nguyen, J.T., McLachlan, D.R., Abraham, C.R. & Kirschner, D.A. α1-antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 61, 298–305 (1993).

    Article  CAS  Google Scholar 

  10. Ma, J., Yee, A., Brewer, H.B. Jr., Das, S. & Potter, H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372, 92–94 (1994).

    Article  CAS  Google Scholar 

  11. Ishiguro, K. et al. Differential expression of α1 -antichymotrypsin in the aged human brain. Virchows Arch. B. Cell Path. 64, 221–227 (1993).

    Article  CAS  Google Scholar 

  12. Wisniewski, K.E. & Kida, E. Proteinase inhibitor α 1-antichymotrypsin has different expression in various forms of neuronal ceroid lipfuscinosis. Exp. Neurol. 110, 121–126 (1990).

    Article  CAS  Google Scholar 

  13. Faber, J.-P. et al. The molecular basis of α1 -antichymotrypsin deficiency in a heterozygote with liver and lung disease. J. Hepatol. 18, 313–321 (1993).

    Article  CAS  Google Scholar 

  14. Strittmatter, W.J. et al. Hypothesis — microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Expl. Neurol. 125, 163–171 (1994).

    Article  CAS  Google Scholar 

  15. Randall, L.L. & Hardy, S.J.S. Unity in function in the absence of consequence in sequence: role of leader peptides in export. Science 243, 1156–1159 (1989).

    Article  CAS  Google Scholar 

  16. Matsubara, E. et al. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. 28, 561–567 (1990).

    Article  CAS  Google Scholar 

  17. Rayford, A., Rao, J.S. & Festoff, B.W. Characterization of the serpin, β1 -antichymotrypsin, in normal human cerebrospinal fluid. J. Neurochem. 58, 88–94 (1992).

    Article  CAS  Google Scholar 

  18. Wisniewski, T., Castano, E.M., Golabek, A., Vogel, T. & Frangione, B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030–1035 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Sanan, D.A. et al. Apolipoprotein E associates with Aβ amyloid peptide to form novel monofibrils: Isoform apoE4 associates more efficiently than apoES. J. Clin Invest. 94, 880–889 (1994).

    Article  Google Scholar 

  20. DeKosky, S.T. et al. Alzheimer's disease and related dementias: report of follow-up on the first 1,000 cases from Pittsburgh. Neurology 44, A354–355 (1994).

    Google Scholar 

  21. McKhann, G. et al. Clinical diagnosis of Alzheimer's disease. Neurology 34, 939–944 (1984).

    Article  CAS  Google Scholar 

  22. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. (3rd revised edn) (Washington, D.C. American Psychiatric Association, (1987).

  23. Khachaturian, Z. Diagnosis of Alzheimer's disease. Arch. Neurol. 42, 1097–1105 (1985).

    Article  CAS  Google Scholar 

  24. Mirra, S.S. et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479–486 (1991).

    Article  CAS  Google Scholar 

  25. Kamboh, M.I., Aston, C.E. & Hamman, R.F. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 112, 145–159 (1995).

    Article  CAS  Google Scholar 

  26. Eichner, J.E., Kuller, L.H., Ferrell, R.E., Meilahn, E.N. & Kamboh, M.I. Phenotypic effects of apolipoproteins structural variation on lipid profiles. III. The contribution of APOE to prediction of total cholesterol, apoB and LDL-C in the Healthy Women Study. Arteriosclerosis 10, 379–385 (1990).

    Article  CAS  Google Scholar 

Download references

Authors
  1. M. Ilyas Kamboh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dharambir K. Sanghera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert E. Ferrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven T. DeKosky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kamboh, M., Sanghera, D., Ferrell, R. et al. A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism. Nat Genet 10, 486–488 (1995). https://doi.org/10.1038/ng0895-486

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0895-486

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing